REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

A chronology of Replimune's RP1 regulatory disclosures alleges that between October 20, 2025 and April 10, 2026, investors were told the FDA resubmission was on track while previously communicated study-design concerns allegedly remained unresolved.

Levi & Korsinsky, LLP reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action on behalf of shareholders who purchased between October 20, 2025 and April 10, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

REPL closed at a Class Period high of $10.73 on December 8, 2025. By April 13, 2026, shares closed at $1.70, a cumulative decline of roughly $9.03 per share, or approximately 84%. Investors have until October 5, 2026 to seek lead plaintiff status.

Chronology of Material Events